VCM
IGMS

Versant Capital Management’s IGM Biosciences IGMS Stock Holding History

Versant Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-169
Closed -$1.03K – 2570
2024
Q4 		$1.03K Hold
169
– – ﹤0.01% 2189
2024
Q3 		$2.79K Buy
+169
New +$1.85K ﹤0.01% 1472

Other funds holding IGMS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Versant Capital Management's IGMS Position: Q1 2025 in Review

Versant Capital Management sold out of IGM Biosciences (IGMS) in Q1 2025, closing a stake of 169 shares — an estimated $1.03K sold.

Versant Capital Management first reported a position in IGMS in Q3 2024 and held it in 2 quarters. The position peaked at $2.79K in Q3 2024. 79 funds tracked by Wall St. Rank hold IGMS as of Q1 2025.

  • Versant Capital Management reported no remaining IGM Biosciences position as of Q1 2025 after selling out during the quarter.
  • Versant Capital Management sold 169 IGM Biosciences shares in Q1 2025, an estimated $1.03K.
  • Versant Capital Management first reported a position in IGM Biosciences in Q3 2024 and held it in 2 quarters.
  • Versant Capital Management's IGM Biosciences position peaked at $2.79K in Q3 2024.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2025.

Based on Versant Capital Management's 13F filing for Q1 2025, filed 3 Apr 2025.